Viridian Therapeutics (VRDN) is back on investors' radar after a rise in institutional ownership and strong year over year gains in quarterly revenue and net profit, which has drawn fresh attention to the stock.

At a share price of $16.63, Viridian Therapeutics has seen its 7 day and 30 day share price returns of 3.04% and 4.13% contrast with a much weaker 90 day share price return, while a 1 year total shareholder return of 10.87% sits against a softer 3 year total shareholder return. This suggests recent momentum has picked up from a lower base.

If you are reassessing biotech risk and reward after Viridian Therapeutics' recent moves, this can be a useful moment to see what else is out there through 41 healthcare AI stocks

With Viridian Therapeutics trading at $16.63, a loss-making P/E of 4.16 and an intrinsic discount of 84.84%, investors are now asking the key question: is this a genuine undervaluation, or is the market already pricing in future growth?

Preferred Price-to-Sales Multiple of 25.9x: Is It Justified?

Viridian Therapeutics is trading at $16.63, and on current revenue the stock carries a P/S multiple of 25.9x, which screens as expensive against several benchmarks.

The P/S ratio compares the company’s market value to its revenue, so a higher multiple usually reflects strong expectations for future sales growth or a valuable pipeline. For a biotech like Viridian Therapeutics that is currently loss making, investors often lean on P/S because earnings are negative and traditional profit based metrics are less informative.

Here, the SWS checks flag that Viridian Therapeutics looks expensive versus an estimated fair P/S of 0x and also versus both direct peers at 14.3x and the broader US biotechs industry at 10.7x. That is a wide gap, and if sentiment or growth expectations shift, there is room for the multiple to move closer to those lower levels.

Result: Price-to-Sales of 25.9x (OVERVALUED)

However, Viridian Therapeutics still faces key risks, including its current net loss of $303.267 million and the possibility that high revenue growth or valuation expectations prove too optimistic.

Another View: What the SWS DCF Model Says About Viridian Therapeutics

While the current P/S of 25.9x makes Viridian Therapeutics look expensive, the SWS DCF model points the other way, with an estimated future cash flow value of $109.67 per share versus the current $16.63 price. That indicates a wide gap, so which story do you trust more?

For a closer look at how that cash flow estimate is built, and what would need to happen for the share price to close that gap, Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Viridian Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 45 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment on Viridian Therapeutics clearly mixed, with both risks and rewards on the table, it can pay to review the numbers quickly and reach your own conclusion by checking the 2 key rewards and 2 important warning signs

Looking For More Investment Ideas Beyond Viridian Therapeutics?

If Viridian Therapeutics has you rethinking your portfolio mix, this is a good moment to scan for other opportunities that match your risk and return preferences.

• Target potential mispricing by reviewing companies highlighted in the 45 high quality undervalued stocks that combine quality fundamentals with attractive valuations.
• Strengthen your defense by focusing on companies in the 66 resilient stocks with low risk scores that score well on resilience and downside protection.
• Get ahead of the crowd by scanning the screener containing 20 high quality undiscovered gems before wider attention pushes these opportunities onto everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.